Pitavastatin Compared with Differential Intervention Trial by Standard Therapy on Cardiovascular Events in Patients with Dyslipidemia on Chronic Hemodialysis (DIALYSIS): A Randomized Controlled Trial

Overview

Journal Blood Purif

Specialty Hematology

Date 2023 Jan 30

PMID 36716708

Authors

Chieko Hamada

Masumi Okuda

Yasuhiko Tomino

Affiliations

Soon will be listed here.

Abstract

Introduction: Statin has been reported to reduce cardiovascular events. However, the comparative efficacy of statin with standard therapy on cardiovascular events has not been sufficiently reported in patients on chronic hemodialysis. Thus, this study aimed to compare the effects of pitavastatin and standard therapy on mortality and cardiovascular events in chronic hemodialysis patients with dyslipidemia in Japan.

Methods: Patients on chronic hemodialysis with dyslipidemia were randomized into pitavastatin-administered (pitavastatin group) or dietary therapy as standard therapy (control) group. Primary outcomes are all-cause mortality and myocardial infarction; secondary outcomes are cardiac arrest and fatal myocardial infarction. The composite outcomes included the incidence of coronary intervention, stroke, fracture, and hospitalization due to heart failure and unstable angina. The clinical outcome analyses used a logistic regression model to categorize the variables. A p value of <0.05 was considered statistically significant.

Results: This study included 848 patients (422 in the control group and 426 in the pitavastatin group) from 79 health facilities. The mean age of the patients was 60.1±10.3 years, and the dialysis period was 7.2±7.6 years. The mean observation period was 36.5 months. The low-density lipoprotein cholesterol level was significantly lower than the baseline value in the pitavastatin group after 12 months of trial (79.8±26.1 vs. 107.8±25.5 mg/dL, p < 0.001). Moreover, the total number of deaths was 85, of which 50 occurred in the control group and 35 in the pitavastatin group. In an analysis adjusted for confounding factors due to participant attributes, there was a significant difference between the control group and the pitavastatin group in the primary and composite endpoints (p = 0.007 and p = 0.022, respectively).

Conclusion: Our study has demonstrated that aggressive intervention with pitavastatin is more effective than the standard (dietary) therapy for improving the clinical outcomes in patients with dyslipidemia on chronic hemodialysis.

Citing Articles

Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association.

Banach M, Surma S, Kaplon-Cieslicka A, Mitkowski P, Dzida G, Tomasik T Arch Med Sci. 2024; 20(1):28-42.

PMID: 38414478 PMC: 10895972. DOI: 10.5114/aoms/175879.

Statins-From Fungi to Pharmacy.

Sadowska A, Osinski P, Roztocka A, Kaczmarz-Chojnacka K, Zapora E, Sawicka D Int J Mol Sci. 2024; 25(1).

PMID: 38203637 PMC: 10779115. DOI: 10.3390/ijms25010466.

References

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

Lee M, Sattar N, McMurray J, Packard C . Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Curr Atheroscler Rep. 2019; 21(10):41. PMC: 6660504. DOI: 10.1007/s11883-019-0800-z. View

Davignon J . Pleiotropic effects of pitavastatin. Br J Clin Pharmacol. 2011; 73(4):518-35. PMC: 3376429. DOI: 10.1111/j.1365-2125.2011.04139.x. View

Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K . A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of.... Clin Ther. 2008; 30(6):1089-101. DOI: 10.1016/j.clinthera.2008.05.017. View

Gregg L, Hedayati S . Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. Am J Kidney Dis. 2018; 72(5):728-744. PMC: 6107444. DOI: 10.1053/j.ajkd.2017.12.007. View

Albers J, Slee A, Fleg J, OBrien K, Marcovina S . Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis. 2016; 251:454-459. PMC: 4983241. DOI: 10.1016/j.atherosclerosis.2016.06.019. View

Mikolasevic I, Zutelija M, Mavrinac V, Orlic L . Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017; 10:35-45. PMC: 5304971. DOI: 10.2147/IJNRD.S101808. View

Balk E, Lau J, Goudas L, Jordan H, Kupelnick B, Kim L . Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med. 2003; 139(8):670-82. DOI: 10.7326/0003-4819-139-8-200310210-00011. View

10.

Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H . Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl. 1999; 71:S134-6. DOI: 10.1046/j.1523-1755.1999.07133.x. View

11.

Huang C, Chan W, Chen Y, Chen T, Chung C, Huang P . The beneficial effects of statins in patients undergoing hemodialysis. Int J Cardiol. 2013; 168(4):4155-9. DOI: 10.1016/j.ijcard.2013.07.115. View

12.

Goodkin D, Bragg-Gresham J, Koenig K, Wolfe R, Akiba T, Andreucci V . Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003; 14(12):3270-7. DOI: 10.1097/01.asn.0000100127.54107.57. View

13.

Marrs J, Saseen J . Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis. Pharmacotherapy. 2010; 30(8):823-9. DOI: 10.1592/phco.30.8.823. View

14.

Saku K, Zhang B, Noda K . Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011; 75(6):1493-505. DOI: 10.1253/circj.cj-10-1281. View

15.

Iseki K, Yamazato M, Tozawa M, Takishita S . Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002; 61(5):1887-93. DOI: 10.1046/j.1523-1755.2002.00324.x. View

16.

Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T . Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb. 2010; 17(6):601-9. DOI: 10.5551/jat.3764. View

17.

da Silva P . Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs. 2011; 11(2):93-107. DOI: 10.2165/11591190-000000000-00000. View

18.

Chapman M . Pitavastatin: novel effects on lipid parameters. Atheroscler Suppl. 2011; 12(3):277-84. DOI: 10.1016/S1567-5688(11)70887-X. View

19.

Ose L, Budinski D, Hounslow N, Arneson V . Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010; 210(1):202-8. DOI: 10.1016/j.atherosclerosis.2009.12.009. View

20.

Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377(9784):2181-92. PMC: 3145073. DOI: 10.1016/S0140-6736(11)60739-3. View